Tumor mutational burden is associated with poor outcomes in diffuse glioma.

ABSTRACT:

Background

Tumor mutational burden (TMB) is a potential biomarker for immune checkpoint therapy and prognosis. The impact of TMB on clinical outcomes and the correlation coefficient between exome sequencing and targeted sequencing in glioma have not yet been explored.

Methods

Somatic mutations in the coding regions of 897 primary gliomas and the clinical and RNA-seq data of 654 patients in The Cancer Genome Atlas (TCGA) database were analyzed as a training set, while another 286 patients in the Chinese Glioma Genome Atlas (CGGA) database were used for validation. Descriptive and correlational analyses were conducted with TMB. Enrichment map analysis and gene set enrichment analysis (GSEA) were also performed.

Results

TMB was higher for the group of mutant genes that a

SUBMITTER: Wang L 

PROVIDER: S-EPMC7069200 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature